Metabolic Acidosis Associated with Potassium-Sparing Drugs

High-Risk Populations and Clinical Presentation

Patients with chronic kidney disease (CKD) are at highest risk of developing metabolic acidosis due to impaired acid-base regulation, according to the American Journal of Kidney Diseases and Annals of Internal Medicine guidelines 1, 2
The American College of Physicians, as reported in Annals of Internal Medicine, recommends careful consideration in patients receiving combination therapy with ACE inhibitors or ARBs, as they have an increased risk of both hyperkalemia and acidosis 2

The Kidney International guideline recommends regular monitoring of serum bicarbonate levels when initiating potassium-sparing diuretics, especially in CKD patients, to prevent metabolic acidosis 3
The American Journal of Kidney Diseases guideline suggests monitoring treatment for metabolic acidosis to ensure it doesn't adversely affect blood pressure control, serum potassium, or fluid status, with a strength of evidence rated as high 3, 4
The Annals of Internal Medicine guideline recommends sodium bicarbonate supplementation to correct acidosis in those with persistent symptoms or severe acidosis, with a moderate strength of evidence 2

The American Journal of Kidney Diseases and Mayo Clinic Proceedings guidelines warn that hyperkalemic metabolic acidosis can lead to cardiac arrhythmias, neuromuscular symptoms, and in severe cases, cardiac arrest, with a high strength of evidence 1, 6
The American Journal of Kidney Diseases guideline notes that metabolic acidosis itself can worsen kidney function and contribute to bone demineralization in chronic cases, with a moderate strength of evidence 4
The British Journal of Pharmacology guideline suggests that in patients with heart failure, the benefits of potassium-sparing diuretics may outweigh the risks of mild acidosis, with a low strength of evidence 7
The Kidney International guideline advises that in patients with advanced CKD (eGFR <25 ml/min/1.73 m²), the risk of severe hyperkalemia and acidosis is significantly higher and may contraindicate these medications, with a high strength of evidence 3